###begin article-title 0
Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study
###end article-title 0
###begin title 1
Introduction
###end title 1
###begin p 2
###xml 20 25 <span type="species:ncbi:10090">mouse</span>
###xml 187 192 <span type="species:ncbi:9606">human</span>
###xml 414 421 <span type="species:ncbi:9606">patient</span>
Previous studies in mouse models and pilot epidemiology studies have demonstrated that inherited polymorphisms are associated with inherited risk of tumor progression and poor outcome in human breast cancer. To extend these studies and gain better understanding of the function of inherited polymorphism in breast cancer progression, a validation prognosis study was performed in a large independent breast cancer patient population.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 45 53 <span type="species:ncbi:9606">patients</span>
The study population consisted of 1863 Dutch patients with operable primary breast cancer from Rotterdam, The Netherlands. Genomic DNA was genotyped for the missense Pro436Leu RRP1B single nucleotide polymorphism (SNP) rs9306160 and the intronic SIPA1 SNP rs2448490 by SNP-specific PCR.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 91 93 91 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 362 364 362 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 561 563 561 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 745 747 745 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
###xml 668 676 <span type="species:ncbi:9606">patients</span>
A significant association of variants in RRP1B with metastasis-free survival was observed (P = 0.012), validating the role of RRP1B with inherited metastatic susceptibility. Stratification of patients revealed that association with patients' survival was found to be specifically restricted to estrogen receptor positive, lymph node-negative (ER+/LN-) patients (P = 0.011). The specific association with metastasis-free survival only in ER+/LN- patients was replicated for SIPA1, a second metastasis susceptibility gene known to physically interact with RRP1B (P = 0.006). Combining the genotypes of these two genes resulted in the significant ability to discriminate patients with poor metastasis-free survival (HR: 0.40, 95% CI: 0.24 to 0.68, P = 0.001).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 473 481 <span type="species:ncbi:9606">patients</span>
These results validate SIPA1 and RRP1B as metastasis susceptibility genes and suggest that genotyping assays may be a useful supplement to other clinical and molecular indicators of prognosis. The results also suggest that lymphatic and hematogeneous metastases are genetically distinct that may involve different mechanisms. If true, these results suggest that metastatic disease, like primary breast cancer, may be multiple diseases and that stratification of late stage patients may therefore be required to fully understand breast cancer progression and metastasis.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
Cancer mortality can be attributed mostly to metastatic disease, with an estimated 90% of deaths associated with solid tumors resulting from the pathophysiological impact of secondary disease. Despite many advances in both basic science and applied clinical research over recent years, advanced disseminated disease remains an incurable condition. Further investigations into the myriad of factors associated with metastatic disease are therefore warranted to identify critical molecular nodes and targets in this complex process that will enable development and deployment of new or improved clinical tools for combating the effects of advanced disseminated disease.
###end p 10
###begin p 11
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 473 474 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 475 476 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 630 631 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
###xml 228 233 <span type="species:ncbi:10090">mouse</span>
###xml 454 459 <span type="species:ncbi:9606">human</span>
One of these factors for breast cancer is inherited metastatic susceptibility. Recently, using a mouse model system, it was demonstrated that germline polymorphisms have significant effects on the ability of a transgene-induced mouse mammary tumor to metastasize [1-3]. Subsequently, using small pilot clinical cohorts, significant associations with markers of poor outcome were observed, consistent with the presence of metastasis susceptibility in the human populations [4,5]. Descriptive epidemiology studies further support this hypothesis, demonstrating familial clustering of outcome in a variety of different cancer types [6-11].
###end p 11
###begin p 12
###xml 127 133 127 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 141 147 141 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
The current study builds on and extends the previous studies of the first two identified metastasis efficiency modifier genes, SIPA1 [3] and RRP1B [4]. Using a much larger cohort, significant associations between polymorphisms in these genes and advanced disease were identified replicating earlier studies. Unexpectedly, however, these associations were restricted to subgroups of patients after stratification by the estrogen receptor (ER) and lymph node (LN) status. The results suggest that at least for inherited metastatic susceptibility in breast cancer that these subpopulations could be biologically distinct with different pathways leading to the metastatic disease.
###end p 12
###begin title 13
Materials and methods
###end title 13
###begin title 14
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient population
###end title 14
###begin p 15
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 554 562 <span type="species:ncbi:9606">patients</span>
###xml 609 617 <span type="species:ncbi:9606">patients</span>
###xml 758 766 <span type="species:ncbi:9606">patients</span>
###xml 808 816 <span type="species:ncbi:9606">patients</span>
###xml 845 853 <span type="species:ncbi:9606">patients</span>
###xml 1057 1065 <span type="species:ncbi:9606">patients</span>
###xml 1172 1180 <span type="species:ncbi:9606">patients</span>
###xml 1193 1201 <span type="species:ncbi:9606">patients</span>
###xml 1291 1299 <span type="species:ncbi:9606">patients</span>
###xml 1455 1462 <span type="species:ncbi:9606">patient</span>
The protocol to study biological markers associated with disease outcome was approved by the medical ethics committee of the Erasmus Medical Center Rotterdam, The Netherlands (MEC 02.953). This retrospective study used coded primary tumor tissue, in accordance with the Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands [12] and, as much as possible, was reported in line with the REMARK guidelines [13]. The single nucleotide polymorphisms (SNPs) were determined in 1863 tumor tissues. ER levels were missing for nine patients and progesterone receptor (PR) levels for 104 patients. Data for one of the two SNPs were not available for 25 tumors. The final study includes breast tumor tissue specimens of 1725 female Dutch patients with primary operable breast cancer (990 patients underwent a mastectomy, 735 patients underwent breast-conserving lumpectomy) who entered the clinic in Rotterdam between 1979 and 2002 with ER and PR levels known as well as both SNPs rs2448490 and rs9306160. Radiotherapy was given to 1162 patients as part of primary treatment. Adjuvant therapy was not performed as part of the primary treatment for LN- patients. Of the LN+ patients, 24% (187 of 766) were received systemic adjuvant therapy. The median follow up of alive patients was 90 months (range, 4 to 231 months). The clinical questions addressed in the present study include the associations of the various SNP frequencies with patient and tumor characteristics, and prognosis in primary breast cancer.
###end p 15
###begin p 16
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
###xml 298 305 <span type="species:ncbi:9606">patient</span>
Tumor ER and PR levels were determined in cytosolic extracts by routine ligand binding assay or by enzyme immunoassay [14]. The cut point to classify primary breast tumors as ER and/or PR positive was 10 fmol/mg cytosolic protein. None of the patients had received neo-adjuvant therapy. Details on patient and tumor characteristics are presented in Table 1.
###end p 16
###begin p 17
###xml 26 33 <span type="species:ncbi:9606">patient</span>
Genotype distributions by patient and tumor characteristics
###end p 17
###begin p 18
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
1Due to missing values the numbers do not always add up to 1863.
###end p 18
###begin p 19
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 5 7 5 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
2All P values derived from Pearson's chi-squared statistics.
###end p 19
###begin p 20
xER = oestrogen receptor; PR = progesterone receptor.
###end p 20
###begin title 21
DNA isolation and whole genome amplification
###end title 21
###begin p 22
###xml 98 101 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
Genomic DNA was isolated from two to ten 30 mum cryostat sections (5 to 20 mg) with the NucleoSpin(R)Tissue kit (Macherey-Nagel; Bioke, Leiden, The Netherlands) according to the protocol provided by the manufacturer. The quantity and quality of the isolated DNA was established by ultraviolet spectroscopy, by examination of the product size after agarose gel electrophoresis, and by the ability of the sample to be linearly amplified by real-time PCR in a serial dilution with a set of primers located in an intron of the hydroxymethylbilane synthase on chromosome 11 and thymidine kinase on chromosome 17. Samples not showing a DNA band of at least 20 kb or at 5 to 25 ng DNA not amplifiable by both real-time PCR assays were excluded. Prior to SNP genotyping, 10 ng aliquots of genomic DNA were amplified with the GenomiPhi V2 DNA amplification kit (GE Healthcare, Piscataway, NJ, USA) according to the protocol provided by the manufacturer, typically yielding 4 mug amplifiable genomic DNA with the 20 kb band still visible on gel.
###end p 22
###begin title 23
SNP selection and genotyping
###end title 23
###begin p 24
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 328 332 328 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174; </sup>
SIPA1 and RRP1B polymorphisms were characterized using allele-specific PCR. PCR primers were designed using Vector NTI 9.0 software (Invitrogen, Carlsbad, CA, USA) according to parameters described elsewhere [15] or purchased from Applied Biosystems (Foster City, CA, USA). Each probe was labeled with a reporter dye (either VIC(R) (a proprietary fluorescent dye produced by Applied Biosystems) or FAM (5-(&6)-carboxyfluorescein)) specific for wildtype and variant alleles of each SNP.
###end p 24
###begin p 25
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 50 51 50 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 193 199 193 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 216 223 216 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSF2BP </italic>
###xml 260 266 260 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 416 422 416 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
The RRP1B SNP rs9306160 was previously described [4]. Briefly, it encodes a Pro436Leu missense mutation in the RRP1B protein, and tags an approximately 200 kb haplotype block encompassing both RRP1B and the adjacent HSF2BP gene. The primers and probes for the RRP1B were as follows, 5'-3': forward, TGGACGTGGCCTCTGCAC; reverse, CACCACCTGCAGCCTGAAA; Vic labeled, AGGGCTTTCGGCCCAG; FAM labeled AGGGCTTTCAGCCCAGAG. The SIPA1 SNP rs2448490 was genotyped using the ABI assay C__15797548_10.
###end p 25
###begin p 26
Reaction mixtures consisted of 300 nM of each oligonucleotide primer, 100 nM fluorogenic probes 8 ng template DNA, and 2x TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA) in a total volume of 10 mul. The amplification reactions were performed in a MJ Research DNA Engine thermocycler (Bio-Rad, Hercules, CA, USA) with two initial hold steps (50degreesC for 2 minutes, followed by 95degreesC for 10 minutes) and 40 cycles of a two-step PCR (92degreesC for 15 seconds, 60degreesC for 1 minute). The fluorescence intensity of each sample was measured post-PCR in an ABI Prism 7900 HT sequence detection system (Applied Biosystems, Foster City, CA, USA), and genotypes were determined by the fluorescence ratio of the nucleotide-specific fluorogenic probes. The genotyping success rate for rs2448490 was 99.2% (2491 of 2511 samples, controls and duplicates). The success rate for rs9306160 was 99.3%. The concordance rate for rs2448490 was 98.3% (404 of 411 duplicates) and 98.1% (404 of 411) for rs9306160.
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
###xml 95 102 <span type="species:ncbi:9606">patient</span>
###xml 433 441 <span type="species:ncbi:9606">patients</span>
Pearson's chi-squared statistic was used to study the relation of the variant SNP alleles with patient and tumor characteristics. The hazard ratios (HRs) for SNPs and traditional prognostic factors were determined with Cox proportional hazards models for both univariate (disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS)) and multivariate regression analyses (with backward elimination) in 1725 patients. The assumption of proportional hazards was checked using Schoenfeld residuals. We stratified for ER because the assumption of proportionality was violated for ER. MFS was considered the major endpoint for the prognostic study. The endpoint for DFS was defined as any recurrence of the disease (958 events) including secondary breast cancer in the contralateral breast. Metastasis was defined as any distant recurrence (772 events) not including secondary breast cancer or local or regional recurrences. For OS, death from any cause was considered an event (n = 684). The HRs are represented with their 95% confidence intervals (CI).
###end p 28
###begin p 29
###xml 309 311 309 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 338 340 338 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
Survival curves were generated using the Kaplan-Meier method, a log-rank test was used to test for differences between the survival curves or when appropriate the log-rank test for trend. Computations were performed with the STATA statistical package, release 10.0 (STATA Corp, College Station, TX, USA). All P values were two-sided, and P < 0.05 was considered statistically significant.
###end p 29
###begin title 30
Results
###end title 30
###begin title 31
SNP selection
###end title 31
###begin p 32
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 335 341 335 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 465 471 465 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 141 148 <span type="species:ncbi:9606">patient</span>
Previous studies with SIPA1 revealed some potential associations with LN metastasis [5], but no significant associations with distant MFS or patient survival [5,16]. Recent examination of the HapMap database [17], however, indicated that the previous SNPs did not tag all of the haplotype blocks for this gene. As a result, the tagged SIPA1 SNP rs2448490 was selected to provide more comprehensive SIPA1 coverage in addition to the previously metastasis associated RRP1B rs9306160 for genotyping in this cohort.
###end p 32
###begin title 33
Analysis of SNP frequencies and tumor characteristics
###end title 33
###begin p 34
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 464 470 464 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 533 535 533 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 545 551 545 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 644 646 644 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 659 661 659 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 676 677 676 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 315 322 <span type="species:ncbi:9606">patient</span>
The SNPs were genotyped in 1863 breast cancer cases. The frequencies of the variant alleles were 37.5% for rs2448490 A and 42.5% for rs9306160 T. rs9306160 was found to be in Hardy-Weinberg equilibrium, while rs2448490 was not in this population. No significant or strong relations of any of the SNP genotypes with patient's age or menopausal status, tumor size, LN status or hormone receptor status were observed (Table 1). Tumors from homozygote carriers of the RRP1B rs9306160 T allele tended to be smaller tumors in this cohort (P = 0.049). SIPA1 SNP rs2448490 was found to be associated with the tumor steroid hormone receptor status (ER, P = 0.087; PR, P = 0.018; Table 1).
###end p 34
###begin title 35
SNP associations with prognosis in primary breast cancer
###end title 35
###begin p 36
###xml 201 207 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 211 217 211 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 132 140 <span type="species:ncbi:9606">patients</span>
SNP allele frequencies were subsequently examined for their associations with prognosis. Survival analyses were conducted for 1,725 patients with both SNPs determined and ER and PR status known. Since SIPA1 and RRP1B had been previously associated with risk of metastatic progression, metastasis-free survival (MFS) was considered the primary endpoint for this study. Disease-free survival (DFS) and overall survival (OS) were included to examine the associations of these genes with disease relapse and overall outcome.
###end p 36
###begin p 37
###xml 43 44 43 44 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 532 534 532 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 581 583 581 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 629 631 629 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 878 879 878 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 1111 1117 1111 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
Consistent with our previous observations [4], patients carrying T allele (CT or TT) of RRP1B SNP rs9306160 showed a favorable prognosis for MFS and the same trends for DFS and OS, when compared with the wildtype CC. Based on these results, the CT and TT patients were grouped together assuming either an additive or dominant effect of the T allele and the univariate analysis repeated. Under this model significant associations of the T allele with better outcome were observed for MFS and OS (DFS (HR: 0.88, 95% CI: 0.77 to 1.01, P = 0.063); MFS (HR: 0.80, 95% CI: 0.69 to 0.92, P = 0.002); OS (HR: 0.85, 95% CI: 0.73 to 1.00, P = 0.046)). Multivariate analysis was then performed to determine whether the T allele was an independent prognostic factor when compared with standard clinical factors. Only the association with MFS was significant in multivariate analysis (Table 2) while the associations of the T allele with DFS and OS were partly confounded in the multivariate analysis and not statistically significant (data not shown). Adjuvant chemotherapy did not affect the estimated coefficients of the RRP1B SNP rs9306160 genotype.
###end p 37
###begin p 38
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Final model for multivariate analysis of MFS in all patients</bold>
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
Final model for multivariate analysis of MFS in all patients1
###end p 38
###begin p 39
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
11725 patients
###end p 39
###begin p 40
CI = confidence interval; ER = estrogen receptor; HR = hazard ratio; MFS = metastasis-free survival; PR = progesterone receptor.
###end p 40
###begin p 41
###xml 410 416 410 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1a</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1b</xref>
###xml 742 744 742 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 791 793 791 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 842 844 842 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
###xml 502 510 <span type="species:ncbi:9606">patients</span>
###xml 545 552 <span type="species:ncbi:9606">patient</span>
As the proportional hazards assumption was violated by ER, we stratified the patients. LN- patients were not treated with systemic adjuvant therapy while LN+ patients did receive systemic treatment. This enabled us to evaluate associations in four subgroups, LN-/ER+ with good prognosis and LN-/ER-, LN+/ER+ and LN+/ER- with an expected poor prognosis. Surprisingly, the association of the variant T allele in RRP1B rs9306160 with a favorable prognosis was significant only for the subgroup of LN-/ER+ patients (Figure 1a), but not in the other patient subgroups (LN+/ER+ (Figure 1b), LN-/ER-, LN+/ER- (not shown)). This association was statistically significant for DFS and MFS in multivariate analysis (DFS (HR: 0.75, 95% CI: 0.60 to 0.94, P = 0.013), MFS (HR: 0.70, 95% CI: 0.54 to 0.91, P = 0.009) and OS (HR: 0.78, 95% CI: 0.59 to 1.03, P = 0.082)).
###end p 41
###begin p 42
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 0 87 0 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kaplan-Meier analysis of MFS for <italic>SIPA1 </italic>and <italic>RRP1B </italic>SNPs on stratified patient populations</bold>
###xml 89 93 89 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(a) </bold>
###xml 93 99 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 169 173 169 173 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(b) </bold>
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 229 233 229 233 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(c) </bold>
###xml 233 239 233 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 289 293 289 293 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(d) </bold>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 328 334 328 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 68 75 <span type="species:ncbi:9606">patient</span>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 279 287 <span type="species:ncbi:9606">patients</span>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier analysis of MFS for SIPA1 and RRP1B SNPs on stratified patient populations. (a) RRP1B rs9306160 in node-negative, estrogen receptor (ER)-positive patients; (b) RRP1B rs9306160 in node-positive, ER-positive patients; (c) SIPA1 rs2448490 in node-negative, ER-positive patients; (d) Combination of SIPA1 rs2448490 and RRP1B rs9306160 in node-negative, ER-positive patients. LN = lymph node; MFS = metastasis-free survival.
###end p 42
###begin p 43
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1c</xref>
###xml 242 244 242 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 283 285 283 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 475 477 475 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 524 526 524 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 575 577 575 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 134 142 <span type="species:ncbi:9606">Patients</span>
The variant A allele of SIPA1 rs2448490 was also found to be associated with better outcome after stratification by ER and LN status. Patients homozygous for the A allele had a favorable MFS (Figure 1c) and OS (HR: 0.57, 95%CI: 0.38 to 0.86, P = 0.007 HR: 0.64, 95%CI: 0.43 to 0.97, P = 0.036). A similar trend, although not statistically significant, was found for DFS. The associations were significant in the multivariate analysis for DFS (HR: 0.73, 95% CI: 0.54 to 0.99, P = 0.042), MFS (HR: 0.56, 95% CI: 0.37 to 0.84, P = 0.005) and OS (HR: 0.59, 95% CI: 0.39 to 0.89, P = 0.012).
###end p 43
###begin title 44
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
SIPA1 SNP rs2448490/RRP1B SNP rs9306160 combination
###end title 44
###begin p 45
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 125 131 125 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 381 387 381 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 405 411 405 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 530 531 530 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 695 701 695 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 751 757 751 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 807 809 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1d</xref>
###xml 1021 1023 1021 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
###xml 619 627 <span type="species:ncbi:9606">patients</span>
###xml 884 892 <span type="species:ncbi:9606">patients</span>
Previous studies demonstrated that the SIPA1 and RRP1B gene products physically interact [4]. As the SIPA1 SNP rs2448490 and RRP1B SNP rs9306160 were both associated with a favorable prognosis in LN-/ER+ patients, we explored the possibility that they were independent predictors of MFS and that the combination of both SNP genotypes might show increased prognostic power. Indeed, SIPA1 SNP rs2448490 and RRP1B SNP rs9306160 remained independent predictors of MFS if both SNPs were included in the final multivariate model (Table 3). Kaplan-Meier analysis for MFS as a function of the combined genotypes in the LN-/ER+ patients showed that the combination of the homozygous AA variant allele of SIPA1 SNP rs2448490 and the T variant allele (CT+TT) of RRP1B SNP rs9306160 was the best prognosticator (Figure 1d). The risk for developing distant metastasis was about 2.5-fold lower for patients with this genotype combination compared with carriers of the GG and GA/CC genotype combination (HR: 0.40, 95% CI: 0.24 to 0.68, P = 0.001).
###end p 45
###begin p 46
###xml 0 79 0 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Final model for multivariate analysis of MFS in ER+ lymph node-negative patient</bold>
###xml 79 80 79 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</bold>
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
Final model for multivariate analysis of MFS in ER+ lymph node-negative patients1
###end p 46
###begin p 47
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 5 13 <span type="species:ncbi:9606">patients</span>
1761 patients
###end p 47
###begin p 48
CI = confidence interval; ER = estrogen receptor; HR = hazard ratio; MFS = metastasis-free survival.
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 473 475 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1172 1174 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1288 1290 1288 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1291 1293 1291 1293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 196 201 <span type="species:ncbi:9606">human</span>
###xml 364 372 <span type="species:ncbi:9606">patients</span>
###xml 484 492 <span type="species:ncbi:9606">patients</span>
###xml 931 938 <span type="species:ncbi:9606">patient</span>
Significant advances have been made in the understanding of breast cancer in the past decade. It is now understood that there are at least four molecular subtypes: luminal A, luminal B, basal and human epidermal growth receptor (HER)2-positive tumors [18]. Furthermore, a variety of studies have demonstrated that gene expression profiles can discriminate between patients of differing outcome. As a result, a number of different commercial assays are currently available [19] to aid patients and clinicians in their decisions for therapeutic intervention, two of which are currently in prospective clinical trials [20,21]. Despite the importance of these findings, the origins of the gene expression signatures are unclear. Based on the prevailing model, it was presumed gene expression signatures would be the result of an accumulation of somatic mutations during the evolution of the tumor. However, the ability to discriminate patient outcome based on bulk tumor expression data was considered inconsistent with that hypothesis, because only a small fraction of the tumor would be predicted to express the appropriate signature, as predicted by the progression model [22]. These observations have led to a renewed discussion into the molecular mechanisms of breast cancer metastasis [23,24].
###end p 50
###begin p 51
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 407 408 407 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 891 893 891 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 684 689 <span type="species:ncbi:9606">human</span>
Studies in our laboratory have suggested that one of the previously unknown factors contributing to breast cancer metastasis is genetic background. Using an animal model system, we demonstrated that the genetic background had a significant impact on its ability to form pulmonary metastases [2]. Subsequently, systems genetics approaches have identified a number of polymorphic metastasis efficiency genes [3,4,25,26]. These results therefore suggest that the prognostic gene expression signatures currently in clinical trials may be in part due to inherited polymorphism rather than somatic mutation, and may be a surrogate for inherited metastasis susceptibility segregating in the human population. This interpretation is strengthened by the recent demonstration that prognostic gene expression signatures pre-exist between normal tissues of animals of high- or low-metastatic genotypes [27]. Taken together, these data support the hypothesis that genotype-based assays may be a valuable complement or supplement to clinical and gene expression-based prognostic tools.
###end p 51
###begin p 52
###xml 132 138 132 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 146 151 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B</italic>
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 590 596 590 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 661 662 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 844 850 844 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 854 860 854 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 861 862 861 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
This study therefore builds on the preliminary epidemiology studies of two of our previously described metastasis efficiency genes, SIPA1 [5] and RRP1B, a chromatin associated protein of unknown function [4,28]. Initial investigations of SIPA1 did not reveal associations with MFS [5,16]. However, recent analysis of HapMap database [17] indicated that the SNPs investigated in these previous studies did not completely haplotype-tag this locus. Therefore an additional SNP was investigated in this study to improve coverage. In contrast, evidence for an association with a polymorphism in RRP1B and MFS had been previously observed in two small pilot cohorts [4]. This study therefore sought to replicate these results in a larger cohort, as well as to investigate whether there was a genetic, in addition to the physical, interaction between RRP1B and SIPA1 [4].
###end p 52
###begin p 53
###xml 803 809 803 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
###xml 199 204 <span type="species:ncbi:9606">human</span>
###xml 938 945 <span type="species:ncbi:9606">patient</span>
The results of these studies suggest a number of important points. First, as predicted by the mouse genetic and pilot epidemiology studies, genetic background is likely to be an important factor for human breast cancer progression because significant associations were observed for both genes. Although the results are consistent with these associations resulting from inherited predisposition an important caveat of this study is that it is also formally possible that these results stem from copy number variation in the tumor DNA used, which is the only material available from this unique cohort. We believe, however, that this is unlikely for the following reasons. First, the results are consistent with the previous studies which were performed in constitutional DNA from normal lymphocytes. For RRP1B at least, this is unlikely to be a false-positive result because the same association has now been observed in three independent patient populations. Second, the allele frequencies of the SNPs does not vary between tumor types and subgroups, as might be expected if there was a preferential copy number change in a subset of tumors. Thus although at this time we can not formally rule out a contribution of somatic evolution we favor the hypothesis that these effects are likely due to inherited factors. Future replication in an independent cohort based on constitutional DNA will be resolve this possibility.
###end p 53
###begin p 54
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1 </italic>
###xml 128 134 128 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
The second major point, as suggested by the physical interaction of the gene products, is that the combination of the SIPA1 and RRP1B SNPs is an independent predictor of MFS when compared with standard clinical parameters, capable of discriminating high-risk, intermediate-risk and low-risk individuals. This combination SNP assay may therefore provide a valuable addition to current methods. This SNP assay would have a number of advantages over current gene expression based assays. As it is based on constitutional DNA it can be performed from routinely collected peripheral blood, rather than tumor tissue, which require more invasive procedures. In addition, because DNA is more stable than RNA, there are fewer constraints on collection, handling and processing procedures. Furthermore, genotyping methods are relatively inexpensive, robust and rapid, and thus would likely be significantly less expensive than expression array based methods.
###end p 54
###begin p 55
###xml 851 853 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 899 901 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1115 1117 1115 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1131 1137 1131 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 </italic>
###xml 1259 1261 1259 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 966 971 <span type="species:ncbi:9606">women</span>
###xml 1375 1382 <span type="species:ncbi:9606">patient</span>
In addition to the potential clinical benefit, this study has important implications for our understanding of the mechanisms of metastatic progression. The fact that these polymorphisms are predictive of MFS in LN-, ER+, but not other subgroups suggest that at least for inherited metastatic susceptibility, there must be at least two pathways for metastatic progression. The lack of association in the LN+ samples indicates that these individuals are not simply diagnosed at a later time along a linear progression pathway. Instead, it suggests that those tumors that spread through the vasculature and those that seed the lymphatics likely use distinct molecular pathways during dissemination. This interpretation is consistent with previous observations in the literature. Analysis of breast cancer subtypes as defined by gene expression profiles [18] demonstrated preferential sites of relapse [29], suggesting different mechanisms of colonization. In addition, women with triple-negative breast cancers (ER-, PR-, HER2-) are less likely to experience a local recurrence before developing a distant recurrence [30]. Similarly, BRCA1 carriers have been shown to be less likely to have positive axillary LNs at diagnosis than non-hereditary breast cancers [31]. To our knowledge, however, this is the first example of the ability of common allelic variants to discriminate patient outcome in specific clinical tumor types.
###end p 55
###begin p 56
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
Although these results are consistent with constitutional predisposition to metastatic disease and suggest that the inherited susceptibilities for tumors that disseminate to the LNs is different than those that metastasize directly distant organs, the mechanisms used are currently unknown. It is possible that the allelic variants of these two genes might significantly alter the likelihood of tumors activating different pathways; for example, angiogenesis versus lymphangiogenesis, which would be expected to help direct tumor cells away from or toward sentinel LNs. At present, however, neither of these genes have been directly implicated in these pathways. SIPA1 is a RAPGAP signaling molecule [32] and RRP1B is a chromatin associated protein of unknown function [28]. Both molecules have been previously implicated in the expression of extracellular matrix genes, which in and of themselves have been associated with metastatic progression. As these variants are present in constitutional DNA the effect of the different alleles on metastatic disease could be due to modulation of tumor cells, the microenvironments the cells encounter or a combination of both. At present it is not clear which of these possibilities is most applicable. Because of these multiple possibilities and the complexity of each component, the exact biological mechanism by which these molecules operate is therefore likely to be complex and require significant additional efforts to unravel the exact mechanistic details.
###end p 56
###begin title 57
Conclusions
###end title 57
###begin p 58
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRP1B </italic>
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SIPA1</italic>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
In summary, this study replicates the previous association of RRP1B with MFS and establishes a previously unknown association with SIPA1. Combination of these SNPs enables effective discrimination of patients into high-risk, intermediate-risk and low-risk categories for MFS, independent of standard clinical parameters. Furthermore, the association of genetic susceptibility for MFS only in specific clinical subgroups indicates that multiple molecular mechanisms for metastatic progression are likely to be involved in breast cancer progression. Further investigations into the utility of these polymorphisms, including validation in additional retrospective cohorts, analysis in prospective clinical trials, and analysis of the effect of the variants on the molecular biology of the tumor and host are clearly warranted to provide further insights into the role of inherited polymorphism in breast cancer dissemination and metastasis.
###end p 58
###begin title 59
Abbreviations
###end title 59
###begin p 60
###xml 81 86 <span type="species:ncbi:9606">human</span>
CI: confidence interval; DFS: disease-free survival; ER: ostrogen receptor; HER: human epidermal growth factor receptor; HR: hazard ratio; LN: lymph node; MFS: metastasis-free survival; OS: overall survival; PCR: polymerase chain reaction; PR: progesterone receptor; SNP: single nucleotide polymorphism.
###end p 60
###begin title 61
Competing interests
###end title 61
###begin p 62
JA Foekens received research support from Veridex LLC. Patent applications filed by NCI for RRP1B genotyping.
###end p 62
###begin title 63
Authors' contributions
###end title 63
###begin p 64
SH performed the genotyping and interpreted the data. ML performed the statistical analysis. AS prepared the samples. JF and KH designed the experiments and interpreted the data. SH, ML, JF and KH wrote the manuscript. All authors read and approved the final manuscript.
###end p 64
###begin title 65
Acknowledgements
###end title 65
###begin p 66
We thank Drs Nigel Crawford and Stefan Ambs for critical comments on this manuscript. This research was supported (in part) by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research to KWH and in part by The Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO) to JAF.
###end p 66
###begin article-title 67
Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1
###end article-title 67
###begin article-title 68
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression
###end article-title 68
###begin article-title 69
Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1
###end article-title 69
###begin article-title 70
Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis
###end article-title 70
###begin article-title 71
Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer
###end article-title 71
###begin article-title 72
Is breast cancer prognosis inherited?
###end article-title 72
###begin article-title 73
Concordance of survival in family members with prostate cancer
###end article-title 73
###begin article-title 74
Survival in breast cancer is familial
###end article-title 74
###begin article-title 75
Survival in bladder and renal cell cancers is familial
###end article-title 75
###begin article-title 76
Familial concordance in cancer survival: a Swedish population-based study
###end article-title 76
###begin article-title 77
Genetic polymorphisms of metastasis suppressor gene NME1 and breast cancer survival
###end article-title 77
###begin article-title 78
Platelet-derived growth factor induction of the immediate-early gene MCP-1 is mediated by NF-kappaB and a 90-kDa phosphoprotein coactivator
###end article-title 78
###begin article-title 79
REporting recommendations for tumor MARKer prognostic studies (REMARK)
###end article-title 79
###begin article-title 80
###xml 91 96 <span type="species:ncbi:9606">human</span>
Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols
###end article-title 80
###begin article-title 81
Characterization of genotype-phenotype relationships and stratification by the CARD15 variant genotype for inflammatory bowel disease susceptibility loci using multiple short tandem repeat genetic markers
###end article-title 81
###begin article-title 82
Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis
###end article-title 82
###begin article-title 83
The International HapMap Project
###end article-title 83
###begin article-title 84
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular portraits of human breast tumours
###end article-title 84
###begin article-title 85
Gene-expression signatures in breast cancer
###end article-title 85
###begin article-title 86
Clinical application of the 70-gene profile: the MINDACT trial
###end article-title 86
###begin article-title 87
TAILORx: trial assigning individualized options for treatment (Rx)
###end article-title 87
###begin article-title 88
A progression puzzle
###end article-title 88
###begin article-title 89
Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population
###end article-title 89
###begin article-title 90
Metastasis: objections to the same-gene model
###end article-title 90
###begin article-title 91
Bromodomain 4 activation predicts breast cancer survival
###end article-title 91
###begin article-title 92
The Diasporin Pathway: a tumor progression-related transcriptional network that predicts breast cancer survival
###end article-title 92
###begin article-title 93
The origins of breast cancer prognostic gene expression profiles
###end article-title 93
###begin article-title 94
The metastasis efficiency modifier Ribosomal RNA Processing 1 Homolog B (RRP1B) is a chromatin-associated factor
###end article-title 94
###begin article-title 95
Subtypes of breast cancer show preferential site of relapse
###end article-title 95
###begin article-title 96
Triple-negative breast cancer: clinical features and patterns of recurrence
###end article-title 96
###begin article-title 97
Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma
###end article-title 97
###begin article-title 98
Rap1 GTPase-activating protein SPA-1 negatively regulates cell adhesion
###end article-title 98

